^
Association details:
| Biomarker: | CXCL8 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer
Excerpt:
...Likewise, the PD activity of ICT01 (by dose and patient population) will include the change from baseline in counts and activation status of Vγ9Vδ2 T cells and other immune cells in the peripheral blood, peripheral blood mononuclear cells (PBMCs) and tumor biopsies, circulating cytokine levels (including IFN gamma, TNF alpha, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17a and MCP-1), and expression of PD-L1, PD-1 and other immune cell markers in tumor biopsies and PBMCs. ...
Trial ID:
Source:
Title:
Response to Pembrolizumab and tumor microenvironment composition is associated with IL8 expression in a head and neck squamous-cell carcinoma cohort
Published date:
11/08/2019
Excerpt:
...IL8 expression was observed to be highest in patients with progressive disease….IL8 expression and neutrophil presence may be related to response to checkpoint therapy in head and neck cancers. Decreased T-cell marker expression in IL8+ regions may reflect decreased response in the larger cohort.
